Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,067 recruiting studies in this area right now.
By phase
- Not applicable3,005
- Phase 21,060
- Phase 1794
- Phase 1/Phase 2441
- Phase 3435
- Phase 4233
- Phase 2/Phase 399
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma328
- Asthma194
- Lymphoma179
- Type 1 Diabetes132
- Rheumatoid Arthritis131
- Atopic Dermatitis122
- Systemic Lupus Erythematosus121
- Acute Lymphoblastic Leukemia118
- HIV Infections105
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases79
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca64
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center49
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California498
- Maryland198
- Alabama178
- Florida151
- Arizona150
- Massachusetts118
- New York114
- Texas112
- Illinois84
- Colorado81
Recruiting studies6,067 total
- NCT05998291Enrolling by invitation
Dermatitis herpetiformis not helped by gluten-free diet
This trial studies two groups of people with dermatitis herpetiformis. One group has a rash that still appears even after following a strict gluten-free diet for at least 3 years. The other group responds well to the diet. The study will compare them to learn more and find better ways to help.
TampereAges 18 years+ - NCT05976555RecruitingPhase 1
CAR T-cell therapy for relapsed myeloma after multiple treatments
This Phase 1 study tests an experimental CAR T-cell treatment that targets BCMA in people with relapsed or refractory multiple myeloma. It may help shrink the cancer after it has not responded to several prior therapies.
Milwaukee, WisconsinAges 18–80 - NCT05991115Recruiting
Hospital to home study for children with asthma
This study helps families whose child is in the hospital for asthma. It aims to make the transition home smoother and reduce asthma-related health differences.
Washington D.C., District of ColumbiaAges 4–12 - NCT03717844Recruiting
Registry for adults with plasma cell disorders
This study is a registry that collects information about adults with plasma cell disorders (conditions involving abnormal antibody-producing cells). It may help researchers understand these diseases better and improve future care by tracking patients over time.
Chapel Hill, North CarolinaAges 18 years+ - NCT04166656RecruitingPhase 3
Meningococcal B vaccine testing for people without a spleen
This Phase 3 trial tests how safe and how well the immune system responds to three different meningococcal B vaccine approaches in people who do not have a spleen. It may help future adults like you choose a safer, more effective prevention strategy against meningococcal B infection.
ParisAges 18–75 - NCT04795882RecruitingPhase 1
Study of modular CAR T therapy for multiple myeloma
This early-phase study tests a personalized type of immune therapy called modular CAR T for people with relapsed or treatment-resistant multiple myeloma. It aims to see whether the therapy can reduce the myeloma, including in cases where standard treatments have not worked.
London, County (Optional)Ages 18 years+ - NCT05370430RecruitingPhase 1
CAR T therapy targeting BAFF-R for certain NHL
This Phase 1 study tests a new type of immune-cell therapy (CAR T cells) that targets BAFF-R to treat certain relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). It aims to see if the treatment is safe and can shrink lymphoma in people who have tried prior therapies.
Duarte, CaliforniaAges 18 years+ - NCT05170126Recruiting
Study of ozanimod use during pregnancy in people with MS
This trial looks at the safety of ozanimod taken during pregnancy for parents with multiple sclerosis and for their babies after birth. It may help doctors understand the risks and benefits of this medicine during early pregnancy.
Bethesda, MarylandAges Any age - NCT05954416Recruiting
Study follow-up for rare skin and related genetic conditions
This study (a “cohort”) follows people with certain rare skin conditions over time. It helps doctors better understand these diseases and improve long-term care, and you may be asked to complete surveys.
BobignyAges Any age - NCT05958381Recruiting
Brain stimulation for memory problems in relapsing MS
This trial studies a noninvasive brain stimulation treatment to improve memory (specifically memory recall) in people with relapsing-remitting multiple sclerosis (RRMS). It may help if your memory testing shows a “retrieval” problem, and if you’re able to follow the study treatment and safety requirements.
Richardson, TexasAges 18–65 - NCT05946564RecruitingPhase 3
Pioglitazone to protect kidney function in ANCA vasculitis
This Phase 3 trial tests whether pioglitazone can help protect kidney function in people with newly diagnosed or relapsing ANCA-associated vasculitis that is actively affecting the kidneys. It aims to improve “renal tolerance,” meaning your kidneys may be better able to tolerate the disease and treatment.
AmiensAges 18–80 - NCT05957913Enrolling by invitationPhase 2
Testing antiviral drugs to control Epstein-Barr virus in MS
This Phase 2 study tests whether certain antiviral medicines can reduce Epstein-Barr virus (EBV) activity. If you have multiple sclerosis and evidence of EBV infection, the results may help clarify new ways to target EBV-related disease activity.
Boston, MassachusettsAges 18 years+ - NCT05947539Enrolling by invitation
Helping Ugandan young women stay engaged in HIV care
This study tests a couples-focused program to help HIV-positive adolescent girls and young women stay connected to HIV clinic visits and medicines. It may help if you’re currently not well engaged in HIV care or you’ve faced partner violence or controlling behavior.
KampalaAges 15 years+ - NCT05956041RecruitingPhase 2
Pembrolizumab and mogamulizumab for advanced relapsed skin lymphoma
This Phase 2 trial studies two immune medicines (pembrolizumab and mogamulizumab) for people with advanced cutaneous T-cell lymphoma that has come back or did not respond to prior treatment. It aims to control the lymphoma and improve outcomes when the disease is hard to treat.
Ann Arbor, MichiganAges 18 years+ - NCT05951816RecruitingPhase 1
Imaging study for amyloidosis in heart and body
This study tests a new imaging agent (99mTc-p5+14) that helps doctors see amyloid deposits in the body, especially in the heart. It is for healthy volunteers and people with AL or ATTR amyloidosis that has affected the heart.
Knoxville, TennesseeAges 18 years+ - NCT05969860RecruitingPhase 2
Home cancer treatment vs clinic treatment for advanced cancer
This Phase 2 trial compares giving certain standard cancer infusions at home versus in a clinic. It may help people avoid clinic visits while still receiving the same cancer treatment safely.
Jacksonville, FloridaAges 18 years+ - NCT05972135RecruitingPhase 2
Outpatient injections for multiple myeloma with teclistamab or talquetamab
This Phase 2 trial tests two antibody medicines (teclistamab or talquetamab) given as outpatient injections, to treat multiple myeloma. It also tests preventing and treating side effects with supportive medicines, aiming to improve disease control in people who have already tried other myeloma treatments.
Tucson, ArizonaAges 18 years+ - NCT05943548Recruiting
Traditional healer support to help HIV reach low viral levels
This study tests whether support from traditional healers can help people with HIV get their viral load down to very low levels. You may be offered additional support and asked to attend clinic and nurse visits over 2 years.
MbararaAges 18 years+ - NCT05955066RecruitingPhase 4
Testing a JAK inhibitor to help RA joint erosion heal
This Phase 4 study tests whether a JAK inhibitor (baricitinib) can improve how RA-related bone erosion heals. You might be eligible if you have rheumatoid arthritis that is still active despite methotrexate treatment, and you meet the specific safety and medication history rules.
Hong Kong, Hong KongAges 18–65 - NCT05952999Enrolling by invitation
Studying Hospital-At-Home care done from home
This trial looks at how well a “Hospital at Home” program works when people start from the emergency department or are already in the hospital and can be cared for at home. It may help teams improve care at home for certain medical conditions and situations.
Peoria, IllinoisAges 18 years+ - NCT05947136Recruiting
PASCA program study after stem cell transplant for myeloma
This study checks whether the PASCA health program helps reduce complications in people with multiple myeloma after their first stem cell transplant. It may help by improving how patients manage side effects during recovery and ongoing treatment.
ÉpagnyAges 18–70 - NCT05963217RecruitingPhase 1
Study of a patient’s own CAR T cells for CD19 cancers
This Phase 1 study tests a personalized form of CAR T cell treatment made from your own immune cells to fight certain CD19-positive blood cancers that have returned or not responded to prior treatment. It mainly looks at safety and how well the treatment can work.
Toronto, OntarioAges 18 years+ - NCT05950724Enrolling by invitationEarly Phase 1
TNF blocker to protect lungs after transplant
This early-stage trial tests whether blocking a specific inflammation signal (TNF-alpha) can help prevent or improve kidney problems and early graft (new lung) dysfunction after a lung transplant at Northwestern. You might be eligible if you’re scheduled for that transplant and are willing to go through study consent and follow-up.
Chicago, IllinoisAges 18 years+ - NCT05961592RecruitingPhase 1
Study drug R-2487 for people with active rheumatoid arthritis
This Phase 1 study tests how the drug R-2487 behaves in the body and looks at early safety in adults with active rheumatoid arthritis. If you have ongoing joint inflammation despite standard treatments, this trial may offer a chance to try an investigational therapy under close monitoring.
San Diego, CaliforniaAges 18–75
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,067 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,241 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.